B of A Securities Maintains Buy on Krystal Biotech, Raises Price Target to $118
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Alec Stranahan maintains a Buy rating on Krystal Biotech (NASDAQ:KRYS) and raises the price target from $105 to $118.
May 22, 2023 | 9:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
B of A Securities analyst maintains Buy rating on Krystal Biotech and raises price target from $105 to $118.
The news of B of A Securities maintaining a Buy rating and raising the price target for Krystal Biotech is positive for the company's stock. This indicates that the analyst has a positive outlook on the company's performance and growth potential, which could lead to an increase in investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100